Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.68 |
| ▸ | ADCY5 | O95622 | 5/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | PI4KA | P42356 | 2/20 | 0.58 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.58 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.58 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17297723 | 0.91 | ADCY5 (0.74) | ADORA2AADORA1ADCY5ADORA2BALDH1A1 | |
| SCHEMBL6045746 | 0.90 | ADCY5 (0.74) | ADORA2AADORA1ADCY5ADORA2BALDH1A1 | |
| SCHEMBL6045556 | 0.89 | ADCY5 (0.75) | ADORA2AADORA1ADCY5ADORA2BALDH1A1 | |
| SCHEMBL6045717 | 0.89 | ADCY5 (0.75) | ADORA2AADORA1ADCY5ADORA2BALDH1A1 | |
| SCHEMBL13882135 | 0.87 | ADORA2A (0.66) | ADORA2AADORA1ADCY5ADORA2BALDH1A1 | |
| SCHEMBL12948654 | 0.85 | ADORA2A (0.68) | ADORA2AADORA1ADCY5ADORA2BALDH1A1 | |
| SCHEMBL1673251 | 0.84 | EGFR (0.70) | ADORA2AADORA1ADCY5ADORA2BALDH1A1 | |
| SCHEMBL6045601 | 0.84 | ADCY5 (0.85) | ADORA2AADORA1ADCY5ADORA2BALDH1A1 | |
| SCHEMBL12922450 | 0.84 | ADORA2A (0.67) | ADORA2AADORA1ADCY5ADORA2BALDH1A1 | |
| SCHEMBL11222112 | 0.84 | ADORA2A (0.80) | ADORA2AADORA1ADCY5ADORA2BPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101157703-A | Adenine bisphosphonate and preparation method thereof and application in pharmaceutical preparations | UNIV HEBEI MEDICAL (CN) | 2008-04-09 | — | — | CN | claimed |
| US-20250258146-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2025-08-14 | — | — | US | disclosed |
| CN-114384756-A | Resin composition, toner for developing electrostatic image, image forming method, photosensitive adhesive, and photoswitch material | 柯尼卡美能达株式会社 | 2022-04-22 | — | — | CN | disclosed |
| EP-1613628-B1 | REVERSIBLE INHIBITORS OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE AND USES THEREOF | GEN ATOMICS (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-1799682-B1 | REVERSIBLE INHIBITORS OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE AND USES THEREOF | GEN ATOMICS (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8168643-B2 | Multiple sclerosis; hemorrhagic virus infection, autoimmune diseases, autograft rejection, neoplasm, hyperhomocysteineuria, cardiovascular disease, stroke, Alzheimer's disease, or diabetes; can be used in combination with an anti-hemorrhagic viral infection agent, immunosuppressant | GENERAL ATOMICS (US) | 2012-05-01 | — | — | US | disclosed |
| US-7868011-B2 | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus | GENERAL ATOMICS (US) | 2011-01-11 | — | — | US | disclosed |
| US-7517887-B2 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | GENERAL ATOMICS (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080194594-A1 | Use of reversible inhibitors of s-adenosyl-l-homocysteine hydrolase for treating lupus | NINGBO ZIYUAN PHARMACEUTICALS, INC. (CN) | 2008-08-14 | — | — | US | disclosed |
| WO-2008086203-A1 | USE OF REVERSIBLE INHIBITORS OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE FOR TREATING LUPUS | GENERAL ATOMICS (US) | 2008-07-17 | — | — | WO | disclosed |
| US-5801184-A | Carbon monoxide dependent guanylyl cyclase modifiers and methods of use | SPECTRUM PHARMACEUTICALS, INC. | 1998-09-01 | — | — | US | disclosed |
| CN-1154065-A | Carbon monoxide dependent guanylyl cyclase effectors | GLASKY ALVIN J (US) | 1997-07-09 | — | — | CN | disclosed |
| EP-0522082-B1 | MULTI-FUNCTIONAL PHARMACEUTICAL COMPOUNDS AND METHODS OF USE | GLASKY ALVIN J (US) | 1997-07-02 | — | — | EP | disclosed |
| EP-0772440-A1 | CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS | GLASKY, Alvin J. (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003125-A1 | CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS | GLASKY ALVIN J (US) | 1996-02-08 | — | — | WO | disclosed |
| US-5447939-A | Purine derivatives used for long term modification of neural activity in mammals, for treatment of mammalian neurological diseases, and for inducing long term changes in membrane potential of mammalian neuron | SPECTRUM PHARMACEUTICALS, INC. | 1995-09-05 | — | — | US | disclosed |
| EP-0522082-A4 | MULTI-FUNCTIONAL PHARMACEUTICAL COMPOUNDS AND METHODS OF USE | — | 1993-06-09 | — | — | EP | disclosed |
| EP-0522082-A1 | MULTI-FUNCTIONAL PHARMACEUTICAL COMPOUNDS AND METHODS OF USE. | GLASKY ALVIN J (US) | 1993-01-13 | — | — | EP | disclosed |
| US-5091432-A | Synergistic | SPECTRUM PHARMACEUTICALS, INC. | 1992-02-25 | — | — | US | disclosed |
| WO-1991014434-A1 | MULTI-FUNCTIONAL PHARMACEUTICAL COMPOUNDS AND METHODS OF USE | GLASKY ALVIN J (US) | 1991-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194594-A1 | Use of reversible inhibitors of s-adenosyl-l-homocysteine hydrolase for treating lupus | AHCY, AHCYL1, BHMT | ADORA2A 70/4885ADORA1 95/4885ADCY5 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.